12/20/2023 0 Comments T cell receptor repertoire analysisWith IGX Explore, immunotherapy companies can boost their target discovery, research and drug development processes. The complete base module, IGX Explore, is now available and can perform clonality analysis of both TCR and BCR repertoires starting from raw sequencing data, report back the number of individual TCR/BCR clones and interactively visualize them in a user-friendly way. It requires no programming skills as the interface is intuitive and flexible. The IGX platform will allow customers to select their own sample preparation protocols and the HTS technology of choice. Starting from high-throughput sequencing data, it will deliver an easy-to-read report appropriate for the specific application, be it research, diagnosis, patient stratification, or treatment monitoring. Finally, IGX Explore outperforms pRESTO with regards to speed and scalability”.Īs announced before, the ImmunoGenomiX (IGX) platform will be modularly expanded to become a comprehensive end-to-end immunosequencing data analysis platform designed to analyze, monitor, and compare immune repertoires in the context of immunotherapy development and at all stages of treatment and disease over time. 2017), we showed that IGX Explore is able to recapitulate the reference immune repertoire composition with high accuracy. On synthetic data, we show that IGX Explore achieves consistent and highly precise performance across all commonly used read lengths, and outperforms pRESTO at short reads lengths in particular, as visualized in the graphs below.įurthermore, using an independently published experimental dataset (Meng W, et al. 2014), the world’s most popular BCR sequencing analysis tool. Specifically, we compared IGX Explore with pRESTO (Vander Heiden, et al. IGX Explore shows superior performance for critical metrics such as correctly identified CDR3 sequences and V/J gene identification. Bonzanni continues: “We benchmarked the performance of IGX Explore for BCRs using both synthetic and experimental datasets. It is with great pleasure that we announce the timely release of the next version of IGX Explore and that our benchmarking studies showed even better performance than expected.”ĭr. antibody) gene somatic hypermutations, the development of a state-of-the-art solution for Ig/BCR sequence analysis offered more extensive challenges for our bioinformatics and software engineering teams. Nicola Bonzanni, ENPICOM’s Chief Scientific Officer, commented: “As BCR analysis harbors additional complexities, such as immunoglobulin (Ig) (i.e. The current functional expansion of IGX Explore adds support for the identification and quantification of B cell receptors (BCRs) from HTS data. Dr. The base module of the IGX platform to perform T cell receptor repertoire analysis, IGX Explore, was launched in August this year. With the IGX platform, ENPICOM is on a mission to provide the immunotherapy community with a best-in-class solution to analyze T cell and B cell receptor (TCR/BCR) immunosequencing data. However, an efficient, integrated, easy-to-use and accurate analytical tool required to process the huge amounts of immunosequencing data has so far been lacking. The improvements in high-throughput sequencing (HTS) technology provide unprecedented opportunities to explore the enormous diversity of the immune repertoire by deep sequencing T cell receptors and B cell receptors. Head-to-head benchmarking studies versus world’s most popular tool, pRESTO, show superiority on several levels. IGX now also accepts B cell receptor (BCR) in addition to T cell receptor (TCR) sequencing data. ‘s-Hertogenbosch, The Netherlands, December 13, 2018 – Today the Dutch bioinformatics software engineering company ENPICOM announced that they have finalized development and released an expanded version of their ImmunoGenomiX (IGX) platform to support discovery and development of novel immunotherapies, patient stratification for, and treatment monitoring of immunotherapies.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |